ProBiotix Health Plc — Director's Dealing 2026

Feb 17, 2026

National Storage Mechanism | Additional information

RNS Number : 2386T

Probiotix Health PLC

17 February 2026

17 February 2026

ProBiotix Health plc

("ProBiotix Health" or the "Company" or, together with its subsidiary, the "Group")

PDMR Shareholding

ProBiotix Health plc (AQSE: PBX), the life sciences business developing probiotics to support cardiometabolic health, is pleased to announce that a PDMR of the Company has acquired 45,100 ordinary shares of 0.05p each in the Company ("Ordinary Shares") as set out in the table below.

For further information, please contact:

ProBiotix Health plc	https://probiotixhealth-ir.com
Steen Andersen, Chief Executive Officer Miles Nolan, Investor Relations	[email protected]
AlbR  Capital Limited Aquis Corporate Adviser and Broker	Tel: 020 7220 9793

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.
1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Michael Litichevski
2	Reason for the notification
a)	Position/status	Vice President, Sales
b)	Initial notification /Amendment	Initial
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer, or auction monitor
a)	Name	ProBiotix Health plc
b)	LEI	98450048683CF0388C30
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument Identification code	ordinary shares of 0.05p each ISIN: GB00BLNBFR86
b)	Nature of the transaction	Acquisition of ordinary shares
c)	Price(s) and volume(s)	45,100 ordinary shares at 6.5p per share
d)	Aggregated information - Aggregated volume - Price	n/a - single transaction
e)	Date of the transaction	16 February 2026
f)	Place of the transaction	Aquis Growth Market

This announcement contains information which, prior to its disclosure, was considered inside information for the purposes of the UK Market Abuse Regulation and the Directors of the Company are responsible for the release of this announcement.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NEXGPUWAPUPQGMQ